Ocular Therapeutix Inc
Suletud
SektorTervishoid
8.93 2.64
Ülevaade
Aktsiahinna muutus
24h
Min
8.61
Max
8.93
Sissetulek | -24M -89M |
|---|---|
Müük | -2.5M 11M |
Aktsiakasum | -0.4 |
Kasumimarginaal | -821.623 |
Töötajad | 325 |
EBITDA | -31M -92M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +170.11% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | -352M 1.8B |
|---|---|
Eelmine avamishind | 6.29 |
Eelmine sulgemishind | 8.93 |
Ocular Therapeutix Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Ocular Therapeutix Inc Prognoos
Hinnasiht
By TipRanks
170.11% tõus
12 kuu keskmine prognoos
Keskmine 23.5 USD 170.11%
Kõrge 31 USD
Madal 18 USD
Põhineb 7 Wall Streeti analüütiku instrumendi Ocular Therapeutix Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
